Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$27.73 ▲ +2.68
(+10.70%)
MKT CAP: $1.44B • VOL: 173.2K
52W L $24 52W H $30
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$23
MEDIAN
$31
MEAN
$32
HIGH
$38
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE LYCA TAPE
LYCA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $33.55 | $31.89 | 2025-02-14 | $25.23 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $34.94 | $32.72 | 2025-02-06 | $26.07 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $31.61 | $30.50 | 2025-01-29 | $26.62 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $28.28 | — | 2025-01-17 | $27.18 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $24.40 | $26.34 | 2025-01-09 | $24.68 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $33.00 | $28.84 | 2024-12-18 | $24.13 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $26.90 | $28.01 | 2024-12-04 | $25.79 | -4.3% | 48% | C |